Open Access

Kadsurenone is a useful and promising treatment strategy for breast cancer bone metastases by blocking the PAF/PTAFR signaling pathway

  • Authors:
    • Tianhui Hou
    • Yan Lou
    • Shichang Li
    • Chenglong Zhao
    • Yingzheng Ji
    • Dongsheng Wang
    • Liang Tang
    • Ming Zhou
    • Wei Xu
    • Ming Qian
    • Zhipeng Wu
    • Jian Zhao
    • Haifeng Wei
    • Zhenxi Li
    • Jianru Xiao
  • View Affiliations

  • Published online on: June 8, 2018     https://doi.org/10.3892/ol.2018.8935
  • Pages: 2255-2262
  • Copyright: © Hou et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Breast cancer (BC) is characterized by high incidences of bone metastases. Current treatment strategies for BC bone metastases primarily focused on breaking the ‘vicious osteolytic cycle’. Platelet‑activating factor (PAF) is a potent phospholipid mediator, which has previously reported biological activities in BC progression and osteoclast differentiation by activating its receptor PAF receptor (PTAFR). However, the role of PAF in the mediation of BC bone metastases remains elusive. In the present study, it was revealed that the upregulation of PTAFR was associated with an increased incidence of bone metastases. It was also revealed that PAF significantly enhanced the processes of BC cell migration and BC mediated osteoclastogenesis. These results suggest that PAF serves a promotion role in BC bone metastases. It was further demonstrated that the natural PAF antagonist Kadsurenone may effectively attenuate each process by partially blocking the PAF/PTAFR signaling pathway. Therefore, targeting PAF/PTAFR by Kadsurenone may be a promising treatment strategy for BC bone metastases.
View Figures
View References

Related Articles

Journal Cover

August-2018
Volume 16 Issue 2

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Hou T, Lou Y, Li S, Zhao C, Ji Y, Wang D, Tang L, Zhou M, Xu W, Qian M, Qian M, et al: Kadsurenone is a useful and promising treatment strategy for breast cancer bone metastases by blocking the PAF/PTAFR signaling pathway. Oncol Lett 16: 2255-2262, 2018
APA
Hou, T., Lou, Y., Li, S., Zhao, C., Ji, Y., Wang, D. ... Xiao, J. (2018). Kadsurenone is a useful and promising treatment strategy for breast cancer bone metastases by blocking the PAF/PTAFR signaling pathway. Oncology Letters, 16, 2255-2262. https://doi.org/10.3892/ol.2018.8935
MLA
Hou, T., Lou, Y., Li, S., Zhao, C., Ji, Y., Wang, D., Tang, L., Zhou, M., Xu, W., Qian, M., Wu, Z., Zhao, J., Wei, H., Li, Z., Xiao, J."Kadsurenone is a useful and promising treatment strategy for breast cancer bone metastases by blocking the PAF/PTAFR signaling pathway". Oncology Letters 16.2 (2018): 2255-2262.
Chicago
Hou, T., Lou, Y., Li, S., Zhao, C., Ji, Y., Wang, D., Tang, L., Zhou, M., Xu, W., Qian, M., Wu, Z., Zhao, J., Wei, H., Li, Z., Xiao, J."Kadsurenone is a useful and promising treatment strategy for breast cancer bone metastases by blocking the PAF/PTAFR signaling pathway". Oncology Letters 16, no. 2 (2018): 2255-2262. https://doi.org/10.3892/ol.2018.8935